A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer

Axel Grothey, Jonathan R. Strosberg, Lindsay A. Renfro, Herbert I. Hurwitz, John L. Marshall, Howard Safran, Michael J. Guarino, George P. Kim, J. R. Hecht, Susan C. Weil, John Heyburn, Wenquan Wang, Charles Schweizer, Daniel J. O'Shannessy, Luis Alberto Diaz

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science